Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer

This study is a randomized, open-label, multi-center investigator-initiated clinical trial. Patients who meet the inclusion criteria receive the treatment plan stipulated in the protocol. A Bayesian design is used to explore the efficacy and safety of teprotumumab combined with pulse chemotherapy in the treatment of advanced second-line extensive-stage small cell lung cancer.

Inclusion Criteria: * 1.Age ≥18 years old, both male and female are acceptable. * 2\. Histology and pathology diagnosis of extensive stage small cell lung cancer, and must meet the following standards: 1. always has not received the immune therapy, 2. Previously received immunotherapy, with the number of treatment lines ≥2 and the immunotherapy being effective(immunotherapy PFS \> 3 months, withdrawal time \> 3 months) 3. never used anlotinib, * 3\. ECOG: 0 \~ 2; * 4 . The expected lifetime 12 weeks or more; * 5\. Major organs function normal Exclusion Criteria: * 1.Those who are allergic to toripalimab or etoposide or have metabolic disorders; * 2.With known the special ripley sheet resistance, etoposide contraindication; * 3.Other circumstances that the researcher assessed as unsuitable for participation in this clinical study.